Objective To probe into the pathogenic mechanisms of paraneoplastic limbic encephali- tis( PL E) in patients with small cell lung carcinoma( SCLC) .Methods The indirect im- munoperoxidase method and Western blotanalys...Objective To probe into the pathogenic mechanisms of paraneoplastic limbic encephali- tis( PL E) in patients with small cell lung carcinoma( SCLC) .Methods The indirect im- munoperoxidase method and Western blotanalysis were used for detecting anti- Hu antibodies in1 6 PLE patients associated with SCL C.Autopsy and pathological study were performed on two cases.Results Eight patients( 5 0 % ) had anti- Hu antibodies( anti- Hu+) whereas eight patients ( 5 0 % ) no detectable antineuronal antibodies ( anti- Hu- ) .The clinical and laboratory features of PLE and time to diagnosis of SCLC were similar in the anti- Hu+and anti- Hu- groups.Involvement of other areas of the nervous system in seven( 87.5 % ) patients of the anti- Hu+group but in only one ( 1 2 .5 ) % of the anti- Hu- group ( P=0 .0 1 2 ) . Conclusions The presence of this characteristic neurological disorder strongly suggested that with an ac- companying SCLC,existence of anti- Hu autoantibody was in favour of an autoimmune mech- anism participating in PLE.展开更多
文摘目的探索以重组真核表达质粒pcDNA3.0/ATP7B进行TX小鼠基因治疗的初步疗效。方法以质粒和脂质体混合后进行尾静脉注射,分别给予TX小鼠pcDNA3.0/APT7B 0、10、20、50、100、150μg,3 d后测定其肝铜含量(ng/mg,即每mg干重的肝组织中铜的含量),确定合适的治疗剂量。然后随机选取36只TX小鼠,随机分成3组,即注射生理盐水组、注射pcDNA3.0组、注射pcDNA3.0/ATP7B组。进行肝脏组织RT-PCR、W estern b lot检测和肝铜含量测定。结果根据预实验结果,取pcDNA3.0/APT7B 100μg/只为治疗剂量。RT-PCR和W estern b lot结果显示,加入pcDNA3.0/ATP7B组于加入后第3、7、14天均可见阳性条带。但以加入第3天时最明显。加入生理盐水组和加入pcDNA3.0质粒组均未见阳性条带。加入pcDNA3.0/APT7B组与生理盐水组及pcDNA3.0组比较,于加入第3、7天肝铜含量显著下降(P<0.05),以第3天下降最明显。加入第14天肝铜含量无显著下降,P>0.05。结论ATP7B基因重组真核表达质粒pcDNA3.0/ATP7B对TX小鼠的铜代谢有改善作用。
文摘Objective To probe into the pathogenic mechanisms of paraneoplastic limbic encephali- tis( PL E) in patients with small cell lung carcinoma( SCLC) .Methods The indirect im- munoperoxidase method and Western blotanalysis were used for detecting anti- Hu antibodies in1 6 PLE patients associated with SCL C.Autopsy and pathological study were performed on two cases.Results Eight patients( 5 0 % ) had anti- Hu antibodies( anti- Hu+) whereas eight patients ( 5 0 % ) no detectable antineuronal antibodies ( anti- Hu- ) .The clinical and laboratory features of PLE and time to diagnosis of SCLC were similar in the anti- Hu+and anti- Hu- groups.Involvement of other areas of the nervous system in seven( 87.5 % ) patients of the anti- Hu+group but in only one ( 1 2 .5 ) % of the anti- Hu- group ( P=0 .0 1 2 ) . Conclusions The presence of this characteristic neurological disorder strongly suggested that with an ac- companying SCLC,existence of anti- Hu autoantibody was in favour of an autoimmune mech- anism participating in PLE.
